Article By:
Quad 7 Capital
Monday, March 5, 2018 2:45 PM EDT
Dermira stock is down heavily today following posted results of to phase 3 pivotal clinical trials for its leading drug candidates for moderate-to-severe acne vulgaris. None of the co-primary endpoint results were statistically significant.
In this article: DERM
